Caribou Biosciences 3Q 2026: Revenue $1.61M, EPS ($0.25) — 10-Q Summary

Caribou Biosciences’ third-quarter revenue declined as the prior-year period included $0.6 million under an expired Pfizer agreement. Net loss narrowed, reflecting lower research and development and general and administrative expenses, partly offset by lower other income, primarily from reduced int…